Peer Review History

Original SubmissionAugust 5, 2021
Decision Letter - Qi Zhao, Editor

PONE-D-21-25185Construction of long non-coding RNA-and microRNA-mediated competing endogenous RNA networks in alcohol-related esophageal cancerPLOS ONE

Dear Mr. Yu Wang,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by November 13th. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Qi Zhao

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. 

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

3. Thank you for stating the following financial disclosure: 

"There are no financial conflicts of interest to disclose."

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." 

If this statement is not correct you must amend it as needed. 

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

4. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ

5. Please include your tables as part of your main manuscript and remove the individual files. Please note that supplementary tables (should remain/ be uploaded) as separate "supporting information" files

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: In this paper, authors downloaded the RNA profiles of patients with alcohol-related and non-alcohol-related EC from The Cancer Genome Atlas (TCGA) database to systematically investigate the lncRNA–miRNA–mRNA interactions related to EC using bioinformatics methods. Identifying susceptible biomarkers can help in better understanding the etiology of EC and then improve the management of this disease. The following are the detailed comments:

1. Spelling and grammar mistakes should be carefully checked in the manuscript.

2. Many computational models were developed to identify disease-related miRNAs and lncRNAs. Authors should introduce some important computational models for them as the future direction of this study (PMIDs: 29939227, 24002109, and 30142158).

3. The method used to predict lncRNA-miRNA interactions and miRNA–target gene interactions should be introduced in more detail in the “Result” section.

4. Each formula presented in the manuscript should be given a corresponding number.

5. Each figure presented in the manuscript is not described in detail.

6. Important reviews about disease-miRNA association prediction and disease-lncRNA association prediction should be emphatically introduced (PMIDs: 29045685 and 27345524).

7. The novelty of this work is not well highlighted. In addition, limitations of the work and work prospects were not provided.

8. I want to know whether the framework proposed in this manuscript is effective for other cancers.

Reviewer #2: In the current manuscript, the authors explored the lncRNA–miRNA–mRNA networks involved in alcohol-related esophageal cancer (EC). They downloaded RNA sequencing and clinical data from TCGA. The lncRNA–miRNA–mRNA competing endogenous RNA (ceRNA) networks were constructed based on the information from miRcode, starBase, and miRTarBase databases. A total of 906 DEGs, 40 DELs, and 52 DEMs were identified. There were eight lncRNAs and eight miRNAs, especially ST7-AS2 and miR-1269, which were significantly associated with the survival rate of patients with EC. Besides, SNHG12–miR-1–ST6GAL1, SNHG3–miR-1–ST6GAL1, SPAG5-AS1–miR-133a–ST6GAL1, and SNHG12–hsa-miR-33a–ST6GA interactions, related to the N-Glycan biosynthesis pathway, may have key roles in alcohol-related EC. However, there are some problems to be further improved before acceptance for publication.

1. Literature review is somewhat incomplete in the introduction, especially about the progress of the bioinformatic analysis about the discovery of ncRNA related with EC.

2. The flowchart in Fig.1 is too simple to show the process very well, please improve it. Also the authors should put Fig.1 before Fig.2.

3. In the Data acquisition section, the authors stated that they downloaded the sequencing data from the TCGA database. Is the authors sure about this? Usually we just download the Gene Expression Quantification data. If the authors processed the raw sequencing data, please write clearly the processing process.

4. Also about the Data acquisition. What is the “paired samples” mean? Were 18 normal samples used in the study? Please make these clearer.

5. Why is the criteria of DEG set to false discovery rate (FDR) < 0.05 and |fold change (FC)| > 1.5?

6. There are some misspellings of software names, such as “miRcorde”, “miRecorde”, “Cystoscope”. Please check these issues carefully.

7. I suggest the authors should discuss more about the meaning of their research in the last section, as they use several online tools.

8. Could the authors give some discussions whether their method and obtained result could be further used to predict EC-related ncRNAs? It could be considered as the future direction of their work. Some recommended studies are helpful (PMIDs: 33588070, 34232474, 34329377; DOI: 10.1016/j.knosys.2019.105261).

9. English expressions need to be edited more careful and more native, in this manuscript, there are some mistakes.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Nana Guan

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Dear editor,

We would like to extend our most sincere gratitude to the reviewers' comments on our manuscript entitled "Construction of long non-coding RNA-and microRNA-mediated competing endogenous RNA networks in alcohol-related esophageal cancer ". Those comments are all valuable and very helpful for revising and improving our paper, as well as the essential guiding significance to our researches. We have revised the comments extensively and have made the corrections in order to meet with approval. The leading corrections in the paper and the response to the reviewers' comments are as follows.

We appreciate for Editors/Reviewers' warm work earnestly and hope that the correction will meet with approval.

Once again, thanks for the comments and suggestions.

Sincerely,

Quan Du

A point-by-point response to reviewer’s comments

Reviewer #1

In this paper, authors downloaded the RNA profiles of patients with alcohol-related and non-alcohol-related EC from The Cancer Genome Atlas (TCGA) database to systematically investigate the lncRNA–miRNA–mRNA interactions related to EC using bioinformatics methods. Identifying susceptible biomarkers can help in better understanding the etiology of EC and then improve the management of this disease. The following are the detailed comments:

Comment 1: Spelling and grammar mistakes should be carefully checked in the manuscript.

Response: Thanks for your valuable comment. The mistakes have been checked and corrected in this revision. In addition, we have sent this manuscript to be edited by professional editors at Editage. The language editing certificate has been provided.

Comment 2: Many computational models were developed to identify disease-related miRNAs and lncRNAs. Authors should introduce some important computational models for them as the future direction of this study (PMIDs: 29939227, 24002109, and 30142158)

Response: Thanks for your valuable comment. We have discussed these computational models in the last paragraph, as follows:

Studies have demonstrated that identification of disease-associted miRNAs/lncRNAs has been will contribute to understand the molecular pathogenesis and to develop molecular tools for the prevention, diagnosis and treatment of diseases (73, 74). In this study, we identified several miRNAs and lnRNAs that significantly associated with alcohol-related EC by using correlation analysis with clinical characteristics and prognosis. In fact, many computational models were developed to identify disease-related miRNAs and lncRNAs (27-29). For example, Chen et al. developed a computational model of Matrix Decomposition and Heterogeneous Graph Inference for miRNA-disease association prediction (29) and developed the method of Laplacian Regularized Least Squares for LncRNA–Disease Association (LRLSLDA) in the semisupervised learning framework (28), these computational models have been confirmed to be effective. Additionally, computational models have been considered as important biological tool for biomedical research, which help to identify the most important miRNAs/lncRNAs-disease associations for experimental validation, markedly decreasing the cost and time for biological experiments (73, 74). Therefore, these computational models should be used for validation our findings and for identifying other potential disease-associated miRNAs and lncRNAs in the future.

Comment 3: The method used to predict lncRNA-miRNA interactions and miRNA–target gene interactions should be introduced in more detail in the “Result” section.

Response: Thanks for your valuable comment. We have revised the descriptions in Result section, as follows:

Prediction of lncRNA–miRNA interactions associated with EC development

To identify the presence of interplay between lncRNAs and miRNAs, the lncRNA–miRNA interactions were retrieved from the miRcode and starBase databases. All the screened DELs were uploaded to both miRcode and starBase databases to predict lncRNA–miRNA interactions. A total of 397 and 429 lncRNA–miRNA interactions were collected from the miRcode and starBase databases, respectively. Totally, 487 lncRNA–miRNA interactions were extracted from these two database after removal of redundancy. Then, 44 lncRNA–miRNA interactions involving DEMs were screened from the 487 lncRNA–miRNA interactions. The 44 lncRNA–miRNA interactions consisted of 13 DELs and 12 DEMs (Fig. 5).

Prediction of miRNA–target gene interactions associated with EC

In silico identification of lncRNA–miRNA interactions relevant to EC progression revealed 12 DEMs. To further predict miRNA–target gene interactions associated with EC, all the potential targets of the 12 DEMs were retrieved from the miRTarBase database. Subsequently, the miRNA-target gene interactions involving DEGs in blue and turquoise modules were screened to construct miRNA-target gene networks, respectively (Fig. 6). The same nine miRNAs (hsa-miR-1, hsa-miR-133a, hsa-miR-143, hsa-miR-16, hsa-miR-205, hsa-miR-33a, hsa-miR-503, hsa-miR-7, and hsa-miR-98) were predicted to target DEGs in in blue and turquoise modules respectively. Fig. 6A showed the miRNA-target gene network consisting of nine miRNAs and their targeted 132 DEGs in blue module. While Fig. 6B showed the miRNA-target gene network consisting of nine miRNAs and their targeted 198 DEGs in turquoise module.

Comment 4: Each formula presented in the manuscript should be given a corresponding number.

Response: Thanks for your valuable comment. We have added a corresponding number for the formula in the manuscript.

Comment 5: Each figure presented in the manuscript is not described in detail.

Response: Thanks for your valuable comment. The figure legends have been described in detail according to your suggestion, as follows:

Figure 2. Cluster analysis of the selected RNAs.

A. The distribution of expression density of mRNAs, miRNAs and lncRNAs. The peak expression density increased after filtering the RNAs with expression level < 1. B. Clustering map of samples based on differential expression of genes, miRNAs, and lncRNAs. In which, the samples in one group tended to cluster together.

Figure 3. Prognosis related lncRNAs and miRNAs.

Univariate Cox regression for differentially expressed lncRNAs and miRNAs identified eight lncRNAs and eight miRNAs were associated with overall survival of patients with alcohol-related esophageal cancer. Kaplan–Meier survival curves showed the survival differences between high and low expression (grouping by median expression value) of the eight prognostic lncRNAs (A) and eight prognostic miRNAs (B).

Figure 4. Identification of the gene modules by weighted gene correlation network analysis (WGCNA).

A. Determination of parameter β of the adjacency function in the WGCNA algorithm. The higher the square value of the correlation coefficient is, the closer the network is to the distribution without network scale. B. Hierarchical cluster analysis dendrogram of gene modules along with corresponding color assignments. Each color represents a certain gene module. C. The correlation between trait values of each module and disease phenotype. Y-axis represent gene significance value, and the gene modules with higher gene significance value were significantly associated with disease phenotype. D. The hierarchical cluster analysis of different modules showed the correlations among different modules. E. The principal component analysis (PCA) analysis of different modules.

Figure 5. DEL–DEM regulatory network.

All the screened DELs were uploaded to both miRcode and starBase databases to predict lncRNA–miRNA interactions, of which 44 lncRNA–miRNA interactions involving DEMs were screened. The network was visualized based on the 44 lncRNA–miRNA interactions. Diamond and square nodes represent miRNAs and lncRNAs, respectively. Red and green colors represent upregulation and downregulation, respectively. DEL, differentially expressed lncRNA; DEM, differentially expressed miRNA.

Figure 6. DEM–DEG regulatory network.

The 12 DEMs in DEL–DEM regulatory network were uploaded to miRTarBase database to predict their targeted genes, and the miRNA-target gene interactions involving DEGs in blue (A) and turquoise (B) modules were screened to construct miRNA-target gene networks, respectively. Diamond and round nodes represent miRNAs and target genes, respectively. Red and green colors represent upregulation and downregulation, respectively. DEM, differentially expressed miRNAs; DEG, differentially expressed genes.

Figure 7. CeRNA regulatory network.

The lncRNA–miRNA interactions, and miRNA-target gene interactions were integrated as lncRNA-miRNA-target genes interactions, and ceRNA network was visualized based on lncRNA-miRNA-target genes interactions. A. The ceRNA network constructed by the DEGs in the blue module. B. The ceRNA network constructed by the DEGs in the turquoise module. Diamond, square, and round nodes represent miRNAs, lncRNAs, and mRNA, respectively. Red and green colors represent upregulation and downregulation, respectively.

Figure 8. The Gene Ontology enrichment analysis of the genes in the ceRNA networks.

A. The analysis of genes in the blue module. B. The analysis of genes in the turquoise module. The Gene Ontology annotation terms consist of molecular function (MF) annotation terms, cellular component (CC) annotation terms and biological process (BP) annotation terms. The length of column represent gene numbers enriched in this annotation term.

Comment 6: Important reviews about disease-miRNA association prediction and disease-lncRNA association prediction should be emphatically introduced (PMIDs: 29045685 and 27345524).

Response: Thanks for your valuable comment. We have discussed these computational models in the last paragraph, as follows:

Studies have demonstrated that identification of disease-associted miRNAs/lncRNAs has been will contribute to understand the molecular pathogenesis and to develop molecular tools for the prevention, diagnosis and treatment of diseases (73, 74). In this study, we identified several miRNAs and lnRNAs that significantly associated with alcohol-related EC by using correlation analysis with clinical characteristics and prognosis. In fact, many computational models were developed to identify disease-related miRNAs and lncRNAs (27-29). For example, Chen et al. developed a computational model of Matrix Decomposition and Heterogeneous Graph Inference for miRNA-disease association prediction (29) and developed the method of Laplacian Regularized Least Squares for LncRNA–Disease Association (LRLSLDA) in the semisupervised learning framework (28), these computational models have been confirmed to be effective. Additionally, computational models have been considered as important biological tool for biomedical research, which help to identify the most important miRNAs/lncRNAs-disease associations for experimental validation, markedly decreasing the cost and time for biological experiments (73, 74). Therefore, these computational models should be used for validation our findings and for identifying other potential disease-associated miRNAs and lncRNAs in the future.

Comment 7: The novelty of this work is not well highlighted. In addition, limitations of the work and work prospects were not provided.

Response: Thanks for your valuable comment. We have added the relevant content in the Discussion section, as follows:

In this paper, the molecular expression characteristics of alcoholic and non-alcoholic EC were systematically analyzed, and some lncRNAs, miRNAs and mRNAs that significantly correlated with clinical characteristics and overall survival of patients were screened out. In addition, the regulatory relationship among these key molecules was investigated. This study provides targets to investigate the pathological mechanism of alcoholic-related EC at molecular level. However, these investigations were concluded based on bioinformatics analysis and warrant further validation for clinical application via additional studies, like immunohistochemistry or quantitative real-time polymerase chain reaction.

Studies have demonstrated that identification of disease-associted miRNAs/lncRNAs has been will contribute to understand the molecular pathogenesis and to develop molecular tools for the prevention, diagnosis and treatment of diseases (73, 74). In this study, we identified several miRNAs and lnRNAs that significantly associated with alcohol-related EC by using correlation analysis with clinical characteristics and prognosis. In fact, many computational models were developed to identify disease-related miRNAs and lncRNAs (27-29). For example, Chen et al. developed a computational model of Matrix Decomposition and Heterogeneous Graph Inference for miRNA-disease association prediction (29) and developed the method of Laplacian Regularized Least Squares for LncRNA–Disease Association (LRLSLDA) in the semisupervised learning framework (28), these computational models have been confirmed to be effective. Additionally, computational models have been considered as important biological tool for biomedical research, which help to identify the most important miRNAs/lncRNAs-disease associations for experimental validation, markedly decreasing the cost and time for biological experiments (73, 74). Therefore, these computational models should be used for validation our findings and for identifying other potential disease-associated miRNAs and lncRNAs in the future. Similarly, we investigated lncRNA-miRNA interactions based on miRcode and starBase databases. While various network algorithms or models have been developed to predict lncRNA-miRNA interactions, which showed superior prediction performance than others (75, 77). In order to screen the most important lncRNA-miRNA interactions, different algorithms or methods should be used in the future. Moreover, circRNAs also play crucial roles in the occurrence and progression of many complex diseases, and several state-of-the-art computational models for predicting circRNA-disease associations have also been developed (78). Thus, investigation of circRNAs that associated with alcohol-related EC using these computational models should be the future direction of our work.

Comment 8: I want to know whether the framework proposed in this manuscript is effective for other cancers.

Response: Thanks for your valuable comment. The framework is also applicative for other cancers.

Thank you again for your valuable comments.

Reviewer #2

In the current manuscript, the authors explored the lncRNA–miRNA–mRNA networks involved in alcohol-related esophageal cancer (EC). They downloaded RNA sequencing and clinical data from TCGA. The lncRNA–miRNA–mRNA competing endogenous RNA (ceRNA) networks were constructed based on the information from miRcode, starBase, and miRTarBase databases. A total of 906 DEGs, 40 DELs, and 52 DEMs were identified. There were eight lncRNAs and eight miRNAs, especially ST7-AS2 and miR-1269, which were significantly associated with the survival rate of patients with EC. Besides, SNHG12–miR-1–ST6GAL1, SNHG3–miR-1–ST6GAL1, SPAG5-AS1–miR-133a–ST6GAL1, and SNHG12–hsa-miR-33a–ST6GA interactions, related to the N-Glycan biosynthesis pathway, may have key roles in alcohol-related EC. However, there are some problems to be further improved before acceptance for publication.

Comment 1: Literature review is somewhat incomplete in the introduction, especially about the progress of the bioinformatic analysis about the discovery of ncRNA related with EC.

Response: Thanks for your valuable comment. We have added the relevant content in the Introduction section, as follows:

Increasing number of studies has revealed the crucial roles of miRNAs/lncRNAs in the pathological progression of EC, including the proliferation, apoptosis, invasion, angiogenesis, metastasis, chemoradiotherapy resistance, as well as stemness of EC, indicating the potential clinical applications value of these non-coding RNAs as diagnostic and prognostic biomarkers (23-26). Many computational models were then developed to identify disease-related miRNAs and lncRNAs (27-29).

Comment 2: The flowchart in Fig.1 is too simple to show the process very well, please improve it. Also the authors should put Fig.1 before Fig.2.

Response: Thanks for your valuable comment. The Figure 1 has been revised, as follows:

All the figures are shown in order. Figure 1 is shown before Figure 2 in our manuscript.

Comment 3: In the Data acquisition section, the authors stated that they downloaded the sequencing data from the TCGA database. Is the authors sure about this? Usually we just download the Gene Expression Quantification data. If the authors processed the raw sequencing data, please write clearly the processing process.

Response: Thanks for your valuable comment. The RNA-seq fragments per kilobase of transcript per million fragments mapped (FPKM) data were downloaded from TCGA database.

Comment 4: Also about the Data acquisition. What is the “paired samples” mean? Were 18 normal samples used in the study? Please make these clearer.

Response: Thanks for your valuable comment. The RNA-seq (miRNAs and mRNAs) profile data of EC and corresponding clinical information were retrieved from TCGA database. A total of 198 mRNA and 198 miRNA sequencing sequenced data were obtained from IlluminaHiSeq_RNASeq and IlluminaHiSeq_miRNASeq sequencing platforms, respectively. The samples of mRNAs seq-data and the samples of miRNA seq-data were matched by the sequencing barcodes, and 190 samples were obtained after matching using sequencing barcodes, including 18 normal and 172 tumor samples. Among the 172 tumor samples, there were 120 alcohol-related EC tumor samples and 50 non-alcohol-related EC tumor samples according to the drinking status of the patients. The rest two samples had no records for drinking status. Finally, the 170 tumor samples were used in the following analysis.

Comment 5: Why is the criteria of DEG set to false discovery rate (FDR) < 0.05 and |fold change (FC)| > 1.5?

Response: Thanks for your valuable comment. The threshold |fold change (FC)| > 1.5 is equal to |log2 FC| > 0.585, which is a very common analytical threshold and has been used in many studies.

Comment 6: There are some misspellings of software names, such as “miRcorde”, “miRecorde”, “Cystoscope”. Please check these issues carefully.

Response: Thanks for your kindest reminding, and these misspellings have been corrected.

Comment 7: I suggest the authors should discuss more about the meaning of their research in the last section, as they use several online tools.

Response: Thanks for your valuable comment. We have added the relevant content according to your suggestion, as follows

In this paper, the molecular expression characteristics of alcoholic and non-alcoholic EC were systematically analyzed, and some lncRNAs, miRNAs and mRNAs that significantly correlated with clinical characteristics and overall survival of patients were screened out. In addition, the regulatory relationship among these key molecules was investigated. This study provides targets to investigate the pathological mechanism of alcoholic-related EC at molecular level. However, these investigations were concluded based on bioinformatics analysis and warrant further validation for clinical application via additional studies, like immunohistochemistry or quantitative real-time polymerase chain reaction.

Comment 8: Could the authors give some discussions whether their method and obtained result could be further used to predict EC-related ncRNAs? It could be considered as the future direction of their work. Some recommended studies are helpful (PMIDs: 33588070, 34232474, 34329377; DOI: 10.1016/j.knosys.2019.105261).

Response: Thanks for your valuable comment. We have discussed these computational models in the last paragraph, as follows (the underlined sentences):

Studies have demonstrated that identification of disease-associted miRNAs/lncRNAs has been will contribute to understand the molecular pathogenesis and to develop molecular tools for the prevention, diagnosis and treatment of diseases (73, 74). In this study, we identified several miRNAs and lnRNAs that significantly associated with alcohol-related EC by using correlation analysis with clinical characteristics and prognosis. In fact, many computational models were developed to identify disease-related miRNAs and lncRNAs (27-29). For example, Chen et al. developed a computational model of Matrix Decomposition and Heterogeneous Graph Inference for miRNA-disease association prediction (29) and developed the method of Laplacian Regularized Least Squares for LncRNA–Disease Association (LRLSLDA) in the semisupervised learning framework (28), these computational models have been confirmed to be effective. Additionally, computational models have been considered as important biological tool for biomedical research, which help to identify the most important miRNAs/lncRNAs-disease associations for experimental validation, markedly decreasing the cost and time for biological experiments (73, 74). Therefore, these computational models should be used for validation our findings and for identifying other potential disease-associated miRNAs and lncRNAs in the future. Similarly, we investigated lncRNA-miRNA interactions based on miRcode and starBase databases. While various network algorithms or models have been developed to predict lncRNA-miRNA interactions, which showed superior prediction performance than others (75-77). In order to screen the most important lncRNA-miRNA interactions, different algorithms or methods should be used in the future. Moreover, circRNAs also play crucial roles in the occurrence and progression of many complex diseases, and several state-of-the-art computational models for predicting circRNA-disease associations have also been developed (78). Thus, investigation of circRNAs that associated with alcohol-related EC using these computational models should be the future direction of our work.

Comment 9: English expressions need to be edited more careful and more native, in this manuscript, there are some mistakes.

Response: Thanks for your valuable comment. The mistakes have been checked and corrected in this revision. In addition, we have sent this manuscript to be edited by professional editors at Editage. The language editing certificate has been provided.

Thank you again for your valuable comments.

Attachments
Attachment
Submitted filename: Response to reviewers.docx
Decision Letter - Qi Zhao, Editor

PONE-D-21-25185R1Construction of long non-coding RNA-and microRNA-mediated competing endogenous RNA networks in alcohol-related esophageal cancerPLOS ONE

Dear Mr. Yu Wang,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by December 28th. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Qi Zhao

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors have addressed all my comments. I think the revised manuscript is acceptable for publication.

Reviewer #2: There are many mistakes in the information of references. The authors should carefully check and revise them. For example, the reference [76] has no journal name and the author’s information is incomplete; the reference information of [77] should be 2020, 191: 105261, and the reference information of [78] should be 2021, 22(6): 1-27 with DOI: 10.1093/bib/bbab286.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Nana Guan

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 2

Dear editor,

We would like to extend our most sincere gratitude to the reviewers' comments on our manuscript entitled "Construction of long non-coding RNA-and microRNA-mediated competing endogenous RNA networks in alcohol-related esophageal cancer ". Those comments are all valuable and very helpful for revising and improving our paper, as well as the essential guiding significance to our researches. We have revised the comments extensively and have made the corrections in order to meet with approval. The leading corrections in the paper and the response to the reviewers' comments are as follows.

We appreciate for Editors/Reviewers' warm work earnestly and hope that the correction will meet with approval.

Once again, thanks for the comments and suggestions.

Sincerely,

Quan Du

A point-by-point response to editor’s and reviewer’s comments

Academic Editor

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Response: Thank you for your valuable comment. We have checked all the references, and no retracted papers are cited in our manuscript.

In this revision, no references are deleted, and doi number are added for references if their doi number are available.

Reviewer #1

The authors have addressed all my comments. I think the revised manuscript is acceptable for publication.

Response: Thank you for your recommendation for our manuscript.

Reviewer #2

There are many mistakes in the information of references. The authors should carefully check and revise them. For example, the reference [76] has no journal name and the author’s information is incomplete; the reference information of [77] should be 2020, 191: 105261, and the reference information of [78] should be 2021, 22(6): 1-27 with DOI: 10.1093/bib/bbab286

Response: Thank you for your valuable comment. We have checked all the references to correct the mistakes.

The revised references 76-77 are as follows:

76. Zhang L, Yang P, Feng H, Zhao Q and Liu H: Using Network Distance Analysis to Predict lncRNA-miRNA Interactions. Interdiscip Sci. 2021. 13 (3):535-545. doi:10.1007/s12539-021-00458-z

77. Liu H, Ren G, Chen H, Liu Q and Zhao Q: Predicting lncRNA-miRNA interactions based on logistic matrix factorization with neighborhood regularized. Knowledge-Based Systems. 2020. 191:105261. doi:10.1016/j.knosys.2019.105261

78. Wang CC, Han CD, Zhao Q and Chen X: Circular RNAs and complex diseases: from experimental results to computational models. Briefings in bioinformatics. 2021. 22 (6):1-27. doi:10.1093/bib/bbab286

Attachments
Attachment
Submitted filename: Response to reviewers.docx
Decision Letter - Yun Zheng, Editor

Construction of long non-coding RNA-and microRNA-mediated competing endogenous RNA networks in alcohol-related esophageal cancer

PONE-D-21-25185R2

Dear Dr. Wang,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Yun Zheng, Ph.D

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: All of my comments have been addressed. I think the revised manuscript is acceptable for publication.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

Formally Accepted
Acceptance Letter - Yun Zheng, Editor

PONE-D-21-25185R2

Construction of long non-coding RNA- and microRNA-mediated competing endogenous RNA networks in alcohol-related esophageal cancer

Dear Dr. Wang:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Yun Zheng

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .